Kodiak Sciences Inc (KOD)

Jun 16, 2025

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion - The Globe and Mail

Jun 16, 2025

Jun 13, 2025

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? - Yahoo Finance

Jun 13, 2025

Jun 10, 2025

Millennium Management LLC Cuts Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World

Jun 10, 2025

Jun 07, 2025

Kodiak Sciences Q2 EPS Forecast Decreased by Zacks Research - Defense World

Jun 07, 2025

Jun 06, 2025

Kodiak Sciences Inc. (NASDAQ:KOD) Position Increased by Public Employees Retirement System of Ohio - Defense World

Jun 06, 2025

Jun 04, 2025

Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 04, 2025

Jun 03, 2025

Kodiak Sciences Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 03, 2025

May 29, 2025

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare C - GuruFocus

May 29, 2025

May 29, 2025

Kodiak Sciences Reveals Latest Retinal Disease Breakthroughs at Major Healthcare Conference - Stock Titan

May 29, 2025

May 29, 2025

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference - Yahoo Finance

May 29, 2025

May 28, 2025

Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads - Investing.com Australia

May 28, 2025

May 27, 2025

Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads By Investing.com - Investing.com India

May 27, 2025

May 25, 2025

Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail

May 25, 2025

May 19, 2025

Kodal Minerals Nears Export Permit For Mali Lithium Project - Finimize

May 19, 2025

May 15, 2025

Kodiak Sciences Inc Reports Q1 2025 Earnings: EPS of -$1.09 Misses Estimates, No Revenue Reported - GuruFocus

May 15, 2025

May 14, 2025

KOD Plans to Unveil Key Developments as Phase 3 Trials Progress - GuruFocus

May 14, 2025

May 14, 2025

KOD Plans to Unveil Key Developments as Phase 3 Trials Progress | KOD Stock News - GuruFocus

May 14, 2025

May 14, 2025

Kodiak Sciences Announces Recent Business Highlights and First Q - GuruFocus

May 14, 2025

May 14, 2025

Kodiak Sciences Reports Deeper Q1 Loss: What 3 Key Phase 3 Trials Mean for Future Growth - Stock Titan

May 14, 2025

May 14, 2025

Kodiak Sciences (KOD) Projected to Post Earnings on Wednesday - Defense World

May 14, 2025

May 13, 2025

Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Dimensional Fund Advisors LP - Defense World

May 13, 2025

May 09, 2025

MetLife Investment Management LLC Makes New $209,000 Investment in Kodiak Sciences Inc. (NASDAQ:KOD) - The AM Reporter

May 09, 2025

May 09, 2025

MetLife Investment Management LLC Invests $209,000 in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World

May 09, 2025

May 09, 2025

Wells Fargo & Company MN Sells 2,710 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World

May 09, 2025

May 07, 2025

Ratio Review: Analyzing Kodiak Sciences Inc (KOD)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

May 07, 2025

May 07, 2025

Retinal vein occlusion Market: Epidemiology, Therapies, - openPR.com

May 07, 2025

May 06, 2025

BlackRock, Inc. Reduces Stake in Kodiak Sciences Inc. - GuruFocus

May 06, 2025

May 02, 2025

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatilit - GuruFocus

May 02, 2025

May 02, 2025

CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics - The Malaysian Reserve

May 02, 2025

May 01, 2025

Breakthrough Eye Disease Platform: Kodiak Sciences Reveals 7 Major Advances at ARVO 2025 - Stock Titan

May 01, 2025

May 01, 2025

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases - Yahoo Finance

May 01, 2025

Apr 30, 2025

Wet Age-Related Macular Degeneration Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight - Barchart.com

Apr 30, 2025

Apr 27, 2025

JPMorgan Chase & Co. Increases Holdings in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World

Apr 27, 2025

Apr 24, 2025

Kodiak Sciences Inc [KOD] Shares Rise 9.62 % on Wednesday - knoxdaily.com

Apr 24, 2025

Apr 24, 2025

A year in review: Kodiak Sciences Inc (KOD)’s performance in the last year - uspostnews.com

Apr 24, 2025

Apr 24, 2025

Insider’s View: Deciphering Kodiak Sciences Inc (KOD)’s Financial Health Through Ratios - DWinneX

Apr 24, 2025

Apr 18, 2025

April 2025's Promising Penny Stocks - Yahoo

Apr 18, 2025

Apr 17, 2025

AMKR Shares Experience Decline in Value - knoxdaily.com

Apr 17, 2025

Apr 17, 2025

Age Related Vision Dysfunction Market to Reach New Heights - openPR.com

Apr 17, 2025

Apr 17, 2025

Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail

Apr 17, 2025

Apr 15, 2025

Why Coffee Prices Remain Volatile - The Globe and Mail

Apr 15, 2025

Apr 12, 2025

Prudential Financial Inc. Sells 65,400 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World

Apr 12, 2025

Apr 11, 2025

Wet Age-Related Macular Degeneration Therapeutics Market Size - openPR.com

Apr 11, 2025

Apr 09, 2025

Sei Investments Co. Sells 69,599 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World

Apr 09, 2025

Apr 04, 2025

Kodiak Sciences stock hits 52-week low at $2.15 - Investing.com India

Apr 04, 2025

Apr 04, 2025

HC Wainwright Comments on Kodiak Sciences Q2 Earnings - Defense World

Apr 04, 2025

Apr 03, 2025

HC Wainwright Forecasts Kodiak Sciences Q1 Earnings - Defense World

Apr 03, 2025

Apr 01, 2025

Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) - Yahoo Finance

Apr 01, 2025